Journal Article Epublish 7 citations
PubMed: 39772087 DOI: 10.3390/vaccines12121427
Post-COVID-19 Vaccination and Long COVID: Insights from Patient-Reported Data.
Vaccines (Basel) 12(12)
Authors: Tom C Quach, Mitchell G Miglis, Lu Tian, Hector Bonilla, Phillip C Yang, Lauren Grossman, Amogha Paleru, Vincent Xin, Anushri Tiwari, Robert W Shafer, Linda N Geng
Affiliations
- Stanford University School of Medicine, Stanford, CA 94305, USA.
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA.
- Department of Biomedical Data Science, Stanford University, Stanford, CA 94305, USA.
- Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
- Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Abstract
INTRODUCTION
COVID-19 vaccinations reduce the severity and number of symptoms for acute SARS-CoV-2 infections and may reduce the risk of developing Long COVID, also known as post-acute sequelae of SARS-CoV-2 (PASC). Limited and heterogenous data exist on how these vaccinations received after COVID-19 infection might impact the symptoms and trajectory of PASC, once persistent symptoms have developed.
METHODS
We investigated the association of post-COVID-19 vaccination with any SARS-CoV-2 vaccine(s) on PASC symptoms in two independent cohorts: a retrospective chart review of self-reported data from patients ( = 128) with PASC seen in the Stanford PASC Clinic between May 2021 and May 2022 and a 2023 multinational survey assessment of individuals with PASC ( = 484).
FINDINGS
Within the PASC Clinic patient cohort ( = 128), 58.6% ( = 75) were female, and 41.4% ( = 53) were male; 50% ( = 64) were white, and 38.3% ( = 49) were non-white. A total of 60.2% ( = 77) of PASC Clinic patients reported no change in their PASC symptoms after vaccination, 17.2% ( = 22) reported improved symptoms, and 22.7% ( = 29) reported worsened symptoms. In the multinational survey cohort ( = 484), 380 were from the U.S., and 104 were from outside the U.S.; 88.4% ( = 428) were female, and 11.6% ( = 56) were male; and 88.8% ( = 430) were white, and 11.2% ( = 54) were non-white. The distribution of survey self-reported vaccine effects on PASC symptoms was 20.2% worsened ( = 98), 60.5% no effect ( = 293), and 19.2% improved ( = 93). In both cohorts, demographic features, including age, sex, and race/ethnicity, were not significantly associated with post-vaccination PASC symptom changes. There was also a non-significant difference in the median dates of COVID-19 infection among the different outcomes. BMI was significant for symptom improvement ( = 0.026) in the PASC Clinic cohort, while a history of booster doses was significant for symptom improvement ( < 0.001) in the survey cohort.
CONCLUSIONS
Most individuals with PASC did not report significant changes in their overall PASC symptoms following COVID-19 vaccinations received after PASC onset. Further research is needed to better understand the relationship between COVID-19 vaccinations and PASC.
MeSH
Vaccines, Vaccination, Signs And Symptoms, Covid-19, Infections, Post-Acute Covid-19 Syndrome